echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sansheng Guojian SSGJ-706 injection obtained the "Notice of Drug Clinical Trial Approval"

    Sansheng Guojian SSGJ-706 injection obtained the "Notice of Drug Clinical Trial Approval"

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On December 27th, Sansheng Guojian issued an announcement stating that the company received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Food and Drug Administration, approving the company's bispecific antibody injection SSGJ-706 to develop in advanced solid tumors and recurrences.
    An open, multi-center, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SSGJ-706 in subjects with refractory lymphoma.
    The company will carry out relevant clinical trials in the near future


    The current anti-PD1 monoclonal antibody/anti-PDL1 monoclonal antibody single agent and combination chemotherapy have shown superior efficacy than previous standard treatments in many tumor fields
    However, PD1/PDL1 inhibitor monotherapy has a low response rate in some patients with advanced solid tumors or needs to be in people with high expression of PDL1 in order to obtain better therapeutic effects.
    This makes it possible to learn from PD1/PDL1 inhibitor monotherapy.
    The people who benefited are limited

    In order to further strengthen the efficacy of immunotherapy, multiple therapies such as dual immune checkpoint inhibitor combination therapy continue to appear.
    Studies have shown that dual antibody inhibitors that target two different targets at the same time have a good therapeutic effect and are compared with two single The incidence of adverse reactions of anti-combination drugs may be low


    SSGJ-706 is a recombinant bispecific antibody developed by Sansheng Guojian using the bispecific antibody platform with independent intellectual property rights.
    It can simultaneously bind two targets closely related to tumor immunosuppressive function, thereby more effectively promoting T cell activation and Proliferation, and further enhance its tumor killing activity

    Its pharmacodynamic studies have confirmed the anti-tumor efficacy of SSGJ-706 in a variety of transplanted tumors

    In addition, non-clinical research data suggest that SSGJ-706 has good safety and tolerability


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.